



## Editorial Excellence and Integrity


Harmful care variations and clinician miscommunication can occur when your organization isn't united on one platform and speaking with one cohesive voice. Clinical effectiveness solutions from Wolters Kluwer are developed to help organizations and professionals harmonize care and reduce unwanted variability by aligning decisions. Care teams in more than 190 countries make evidence-based decisions with Lexicomp®, Medi-Span®, and UpToDate® in their workflow, and empower patients to participate in their care with Emmi® programs.

Our multidisciplinary editorial team considers new evidence in the context of existing best practices to make actionable recommendations for care that align across our suite of solutions. Our rigorous process seeks to balance the timely review and interpretation of new information with the need of professionals to access new evidence and practice-changing updates as promptly as possible.

### Our Drug Information Editorial Team

- **150+** specialists (more than **70** pharmacists, plus doctors, nurses, technical and editorial support )
- Majority have advanced training (PharmD or PhD) and extensive clinical experience (typically 10+ years) covering key pharmacology areas:
  - Cardiology
  - Critical care
  - Drug interactions
  - Formulary expertise
  - Geriatrics
  - Infectious diseases
  - Neonatology
  - Nephrology
  - Nutrition
  - Oncology
  - Patient education
  - Pediatrics
  - Pharmacogenomics
  - Pregnancy and lactation
  - Psychiatry
  - Women's health
- **260+** expert consultants with specific subspecialty expertise

### The Power of One Voice: Our Editorial Process



## Our Editorial Philosophy

- Cross-functional, multidisciplinary (physician, pharmacist) content teams work with a goal to ensure Lexicomp and UpToDate are aligned and share clinical insights to provide valuable context for decision making.
- Our goal is to provide evidence-based, clinically actionable information to aid healthcare practitioners in choosing an appropriate and safe drug and dose for the patient based on the best available evidence.
- Drug monographs are developed in a clear, concise presentation for use at the point of care.
- Our content is developed using strict editorial policies that are intended to represent the content in a balanced, unbiased way.



## How We Develop Our Proprietary Content

### *Creating New Monographs*

- Initiated with new FDA or Health Canada approvals or publications from regulators, manufacturers, and scientific researchers.
- Development begins with a variety of sources including product labeling, clinical trials, clinical practice guidelines, and UpToDate.

### *Developing Content*

Our experts perform daily surveillance on industry activity and primary literature so that our information reflects current medical practices.

- Content is synthesized, managed, and reviewed by a team of around 150 clinicians:
  - Full-time, in-house clinical teams include more than 70 pharmacists, as well as physicians, nurses, and laboratory experts
- Medication patient education and drug interaction information are updated concurrently with drug monographs.

### *Continuous Expert Review and Updating*

Once monographs are published, our experts continually review the medical literature and relevant medical information (e.g., adverse drug reaction reports, clinical practice guidelines) for new evidence and updates that should be made to monographs. This includes:

- Medical journals
- International regulatory bodies and professional societies
- Industry sources for product labeling and dosage form information
- U.S. government agencies

### HOW CAN YOU CONTRIBUTE?

Our editorial team is receptive and responsive to your feedback, as we strive to keep our content clinically relevant and useful.

**Use the feedback link in Lexicomp and UpToDate.**